Literature DB >> 22269622

Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.

Jacques Baillargeon1, Holly M Holmes, Yu-Li Lin, Mukaila A Raji, Gulshan Sharma, Yong-Fang Kuo.   

Abstract

BACKGROUND: Antibiotic medications are associated with an increased risk of bleeding among patients receiving warfarin. The recent availability of data from the Medicare Part D prescription drug program provides an opportunity to assess the association of antibiotic medications and the risk of bleeding in a national population of older adults receiving warfarin.
METHODS: We conducted a case-control study nested within a cohort of 38,762 patients aged 65 years and older who were continuous warfarin users, using enrollment and claims data for a 5% national sample of Medicare beneficiaries with Part D benefits. Cases were defined as patients hospitalized for a primary diagnosis of bleeding and were matched with 3 control subjects on age, race, sex, and indication for warfarin. Logistic regression analysis was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the risk of bleeding associated with prior exposure to antibiotic medications.
RESULTS: Exposure to any antibiotic agent within the 15 days of the event/index date was associated with an increased risk of bleeding (aOR 2.01; 95% CI, 1.62-2.50). All 6 specific antibiotic drug classes examined (azole antifungals [aOR, 4.57; 95% CI, 1.90-11.03], macrolides [aOR, 1.86; 95% CI, 1.08-3.21], quinolones [aOR, 1.69; 95% CI, 1.09-2.62], cotrimoxazole [aOR, 2.70; 95% CI, 1.46-5.05], penicillins [aOR, 1.92; 95% CI, 1.21-2.07], and cephalosporins [aOR, 2.45; 95% CI, 1.52-3.95]) were associated with an increased risk of bleeding.
CONCLUSION: Among older continuous warfarin users, exposure to antibiotic agents-particularly azole antifungals-was associated with an increased risk of bleeding.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22269622      PMCID: PMC3712345          DOI: 10.1016/j.amjmed.2011.08.014

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.

Authors:  J P Rindone; C L Kelley; W N Jones; H S Garewal; C L Keuey
Journal:  Clin Pharm       Date:  1991-02

2.  Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin.

Authors:  N P Beckey; D Parra; A Colon
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

3.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

4.  Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding.

Authors:  H Schelleman; W B Bilker; C M Brensinger; X Han; S E Kimmel; S Hennessy
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

Review 5.  Interactions between warfarin and three commonly prescribed fluoroquinolones.

Authors:  Douglas N Carroll; Dana G Carroll
Journal:  Ann Pharmacother       Date:  2008-04-15       Impact factor: 3.154

6.  Determination of the lack of a drug interaction between azithromycin and warfarin.

Authors:  Kenneth L McCall; H Glenn Anderson; Angela D Jones
Journal:  Pharmacotherapy       Date:  2004-02       Impact factor: 4.705

Review 7.  Azithromycin and warfarin interaction.

Authors:  Sarah P Shrader; Joli D Fermo; Amy L Dzikowski
Journal:  Pharmacotherapy       Date:  2004-07       Impact factor: 4.705

8.  Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.

Authors:  T M Bianco; H I Bussey; L E Farnett; W D Linn; M K Roush; Y W Wong
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

9.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

10.  Retrospective assessment of potential interaction between levofloxacin and warfarin.

Authors:  Gabriel Mercadal Orfila; Berta Gracia García; Elisabet Leiva Badosa; María Perayre Badía; Concepción Reynaldo Martínez; Ramón Jodar Masanés
Journal:  Pharm World Sci       Date:  2008-12-06
View more
  28 in total

1.  Drug interaction resulting in massive chest wall hematoma in a patient on therapeutic anticoagulation.

Authors:  Pradeep Rangappa; Tejaswini Arunachala Murthy; Ipe Jacob
Journal:  Indian J Crit Care Med       Date:  2015-04

Review 2.  Antithrombotic drugs: pharmacology and implications for dental practice.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2013

3.  Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Authors:  Michael A Lane; Angelique Zeringue; Jay R McDonald
Journal:  Am J Med       Date:  2014-03-19       Impact factor: 4.965

4.  Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Walter E Smalley; James R Daugherty; William D Dupont; C Michael Stein
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

5.  Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.

Authors:  Carrie Tilton; Spencer Livengood; Jeremy Hodges; Jessica Marshall
Journal:  Hosp Pharm       Date:  2018-05-18

6.  Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.

Authors:  L Gschwind; V Rollason; C Lovis; F Boehlen; P Bonnabry; P Dayer; J A Desmeules
Journal:  Eur J Clin Pharmacol       Date:  2012-08-19       Impact factor: 2.953

Review 7.  Antimicrobial drugs.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2013

8.  Dosage individualization of warfarin using artificial neural networks.

Authors:  Mohammad I Saleh; Sameh Alzubiedi
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

Review 9.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

10.  Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.

Authors:  Sven Schmiedl; Marietta Rottenkolber; Jacek Szymanski; Werner Siegmund; Marion Hippius; Katrin Farker; Bernd Drewelow; Joerg Hasford; Petra Thürmann
Journal:  Dtsch Arztebl Int       Date:  2013-04-05       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.